Rheumatoid Lung Disease: Causes, Symptoms, and Care

Rheumatoid arthritis (RA) is a chronic autoimmune disease. It is known to primarily affect the joints, but extra-articular manifestations are common, and among these, perhaps the most common are pulmonary complications. ‘Rheumatoid lung disease’, in simple terms, is a basket term that includes a whole spectrum of lung problems. This spectrum includes interstitial lung disease (ILD), rheumatoid nodules, pleural disease, airway disorders, and drug-induced toxicity.

And these lung complications are not minor either; in fact, they remain one of the major causes for morbidity and mortality among patients with RA. Therefore, the significance of early identification and treatment cannot be overstated. The problem is that patients with lung involvement present with varied atypical patterns, and hence can be challenging to diagnose and manage.

Epidemiology & Causes

• Approximately 60–80% of patients with RA show evidence of pulmonary abnormalities on sensitive imaging like high-resolution computed tomography (HRCT)^[1], though the majority of these cases are subclinical and asymptomatic. Among these, a smaller subset develops symptomatic pulmonary disease.
• Interstitial lung disease is the most significant subtype overall, causing the majority of pulmonary deaths (10-20% of all RA deaths)^[2], and decreases overall life expectancy.

Risk Factors:

• Male sex
• Old age
• Cigarette smoking (the strongest modifiable factor)
• Seropositivity for RF and anti-CCP antibodies
• High antibody titers
• Methotrexate and other DMARD therapy

The relationship between smoking and RA lung disease deserves particular emphasis. Cigarette use doesn’t simply increase risk. It fundamentally alters immune responses by promoting protein citrullination in lung tissue, potentially activating the autoimmune cascade that represents both articular and pulmonary disease.^[3]

Pathophysiology of Rheumatoid Lung Disease

Similar pathologic processes as in the articular disease affect the lung because of the overlapping mechanisms. Chronic inflammation results in gene regulation and activated immune cells release cytokines (TNF-α, IL-6, IL-1), which trigger fibroblast activation and abundant extracellular matrix production.

Primary Disease Mechanisms:

• Autoimmune inflammation: T-cell and macrophage activation leading to cytokine release
• Fibrotic processes: Unchecked fibrosis resulting in Usual Interstitial Pneumonia (UIP) or Nonspecific Interstitial Pneumonia (NSIP) patterns
• Granulomatous inflammation: Formation of discrete nodules similar to subcutaneous lesions
• Airway involvement: Chronic changes causing bronchiectasis and small airway disease
• Pleural inflammation: Immune-mediated pleuritis producing exudative effusions
• Drug toxicity: Methotrexate hypersensitivity or chronic fibrosis^[4]

Immunological pathway in RA-ILD. Activated immune cells release cytokines (black arrows), driving lung inflammation and fibrosis via upregulated FMT (red arrow). (Image Courtesy: Kim, Y., Yang, H., & Kim, K. (2022). Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease. International Journal of Molecular Sciences, 24(19), 14509. Available fromMDPI. Licenced under CC by 4.0)

Environmental agents, mainly smoking, amplify these pathophysiology mechanisms by increasing protein citrullination and autoimmune responses. This is probably the reason why smokers with RA experience both higher incidence and more severe lung involvement.

Clinical Features of Rheumatoid Lung Disease

In rheumatoid arthritis, pulmonary involvement advances gradually in most cases. Some patients are asymptomatic, in which lung abnormalities are only detected coincidentally when they appear on screening studies. Some patients start noticing symptoms after some time, e.g., shortness of breath on climbing stairs.
When symptoms do develop and become apparent, they differ a lot in their patterns based on the affected pulmonary structures.

Rheumatoid Lung Disease Symptoms:

• Progressive exertional dyspnea (presenting complaint)
• Chronic dry cough
• Pleuritic chest pain (suggests pleural involvement)
• General symptoms (fever, fatigue, weight loss)
• Hemoptysis (rare; may indicate cavitating nodules)

Signs on Physical Examination:

• Fine inspiratory crackles (“Velcro” crackles in ILD)^[5]
• Digital clubbing (more common with UIP pattern)
• Pleural friction rubs or decreased breath sounds
• Hypoxemia at rest or with exertion
• Wheezing or ronchi (airway disease)

Digital clubbing in a patient with interstitial lung disease. (Image Courtesy: Canna, S.W., Schulert, G.S., de Jesus, A. et al. Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatr Rheumatol 18 (Suppl 1), 53 (2020). Available fromBMC. Licenced under CC by 4.0)

Pattern-Specific Presentations:

Interstitial Lung Disease

Progressive dyspnea and nonproductive cough dominate the clinical picture. Advanced cases may present with cyanosis, cor pulmonale, and respiratory failure. The UIP pattern typically shows more rapid progression compared to NSIP patterns.

Rheumatoid Nodules

Most remain asymptomatic and are discovered incidentally on imaging. Cavitated nodules may cause cough, hemoptysis, or predispose to pneumothorax.^[6] Secondary infections represent a significant complication.

Bronchiectasis

Characterized by chronic productive cough, recurrent infections, and potential hemoptysis. Patients frequently develop colonization with resistant pathogens, including Pseudomonas species.

Pleural Disease

Sharp pleuritic chest pain and dyspnea from effusions are typical. Recurrent unilateral effusions represent a characteristic pattern in RA patients.

Diagnosis of Rheumatoid Lung Disease

Because of how dangerous lung involvement in RA can be, it’s all the more important to diagnose it on time. Early diagnosis requires high clinical suspicion combined with systematic evaluation.
The combination of clinical assessment, imaging, and functional testing provides the foundation for accurate diagnosis while excluding important mimics.

Clinical Assessment:

• History: Respiratory symptoms, drug exposure, smoking status
• Risk stratification: Male sex, older age, seropositivity
• Physical examination: Pulmonary findings, clubbing, chest expansion

Essential Investigations:

Pulmonary Function Tests7Hassan, A.M., Osman, A.A. & Ali, I.A. Pulmonary functions test in asymptomatic rheumatoid lung disease patients: a hospital-based study. Discov Med 1, 9 (2024). https://doi.org/10.1007/s44337-024-00013-x

• Restrictive pattern: Decreased TLC and FVC
• Reduced DLCO (often the first abnormality)
• Serial monitoring for disease progression

Imaging Studies

• Chest X-ray: Low sensitivity, may show reticular infiltrates or effusions
• HRCT (Gold Standard)^[7]:

Additional Studies:

• RF and anti-CCP antibodies (supportive but nonspecific)
• Infection screening, including tuberculosis
• Bronchoscopy/biopsy when diagnosis is uncertain

Differential Diagnoses:

Because RA-ILD can mimic several conditions, differential diagnosis is essential:

Feature	RA-ILD	Idiopathic Pulmonary Fibrosis (IPF)9Sankari A, Chapman K, Ullah S. Idiopathic Pulmonary Fibrosis. [Updated 2024 Apr 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448162/	Sarcoidosis	Methotrexate Pneumonitis
Onset	Insidious, chronic	Gradual, progressive	Variable (acute or chronic)	Acute/subacute
Association	Established RA	No systemic disease	Multisystem granulomatous	Methotrexate therapy
HRCT	UIP/NSIP, nodules	Predominantly UIP	Hilar lymphadenopathy, nodules	Diffuse ground-glass
Serology	RF, anti-CCP positive	Negative	ACE ↑, calcium ↑	Not specific
Treatment response	Variable to immunosuppression	Poor	Steroid-responsive	Improves after drug withdrawal

Classification/ Clinical Staging

Unlike articular rheumatoid arthritis, rheumatoid lung disease does not have a universally adopted staging system. However, clinicians often classify it according to radiologic pattern, histopathology, and physiologic severity.

Radiologic/Histopathologic Patterns:

High-resolution CT (HRCT) is the primary diagnostic tool, with lung biopsy reserved for atypical or unclear cases. The following subtypes are most commonly recognized:

• UIP: Honeycombing, progressive fibrosis, poor prognosis
• NSIP: Ground-glass changes, better treatment response
• Organizing Pneumonia: Patchy consolidations, highly steroid-responsive
• Rheumatoid Nodules: Well-circumscribed, risk of complications
• Pleural Disease: Recurrent effusions, often asymptomatic

High-resolution CT (HRCT) findings in RA-associated interstitial lung disease (RA-ILD). (A) Usual interstitial pneumonia (UIP): reticular fibrosis, traction bronchiectasis, and subpleural honeycombing. (B) Nonspecific interstitial pneumonia (NSIP): ground-glass opacities with septal thickening and variable fibrosis. (C) Lymphocytic interstitial pneumonia (LIP): perivascular thin-walled cysts (black arrows). (D) Organizing pneumonia (OP): patchy pulmonary consolidations (white arrow). (Image Courtesy: Laria, A., Lurati, A. M., Zizzo, G., Zaccara, E., Mazzocchi, D., Re, K. A., Marrazza, M., Faggioli, P., & Mazzone, A. (2022). Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. Frontiers in Medicine, 9, 837133. Available fromFrontiers. Licenced under CC by 4.0)

Physiologic Severity (PFT-Based):

Doctors use pulmonary function tests (PFTs) to measure how well the lungs are working. These tests help stage the severity of rheumatoid lung disease and track its progression over time. Two key values are checked:

• DLCO (Diffusing Capacity): how well the lungs transfer oxygen into the blood.
• FVC (Forced Vital Capacity): how much air a person can exhale after a deep breath.

Stage	FVC (% predicted)	DLCO (% predicted)	Clinical Implication
Mild	>70%	>65%	Often subclinical, requires monitoring
Moderate	50–70%	40–65%	Symptomatic, treatment consideration warranted
Severe	<50%	<40%	Advanced disease, high mortality risk

Treatment & Management of Rheumatoid Lung Disease

Managing rheumatoid lung disease requires balancing the treatment of underlying RA with preservation of pulmonary function. The heterogeneous nature of lung involvement, potential drug toxicities, and need to control systemic disease make this particularly challenging. A multidisciplinary approach involving both rheumatology and pulmonology is strongly recommended.

Treatment strategies depend heavily on identifying the predominant pattern of lung involvement and excluding mimics before initiating therapy.

Step 1. Universal Measures:

• Baseline assessment with PFTs and HRCT before treatment decisions
• Exclude active infection or drug-induced toxicity
• Smoking cessation counseling and support
• Vaccination (influenza, pneumococcal, COVID-19)
• Pulmonary rehabilitation when appropriate

Step 2. Pattern-Based Treatment Strategies:

Inflammatory Disease (NSIP, Organizing Pneumonia, Active Alveolitis)

These patterns typically respond better to immunosuppressive therapy compared to established fibrotic disease.

• First-line therapy: Glucocorticoids (prednisone 0.5-1 mg/kg daily)
• Steroid-sparing agents: Mycophenolate mofetil, azathioprine, or cyclophosphamide for recurrent/progressive disease
• Biologic DMARDs: Rituximab or abatacept preferred when systemic RA activity requires control^[8]

Fibrotic Disease (UIP Pattern, Progressive Fibrosing Phenotype)

These cases show limited response to traditional immunosuppression and require different approaches.

• Limited corticosteroid response expected
• Antifibrotic therapy: Consider nintedanib or pirfenidone
• Early transplant referral for progressive disease in appropriate candidates
• Focus on supportive care and symptom management

Pleural Disease

Most cases are self-limited, but symptomatic patients may require intervention.

• Conservative management: NSAIDs for pain relief
• Drainage: Therapeutic thoracentesis for large, symptomatic effusions
• Pleurodesis: Consider for recurrent, problematic effusions

Rheumatoid Nodules

• Asymptomatic nodules: Observation with serial imaging
• Large or symptomatic nodules: Surgical excision may be indicated
• Complications management: Pneumothorax drainage, infection treatment

Bronchiectasis

Management focuses on airway clearance and infection prevention.

• Airway clearance: Chest physiotherapy, inhaled bronchodilators
• Infection management: Appropriate antibiotics for acute exacerbations
• Maintenance therapy: Consider macrolides for recurrent infections

Step 3. Choosing Safe RA Therapy in the Context of ILD:

The choice of disease-modifying therapy requires careful consideration of pulmonary safety profiles.

DMARDs (Disease-modifying antirheumatic drugs) to Avoid

• TNF inhibitors: Associated with ILD progression and reactivation^[9]
• Leflunomide: Can precipitate interstitialpneumonitis

Preferred Agents

• Rituximab: Good safety profile, effective for both RA and some ILD patterns
• Abatacept: Generally well-tolerated in lung disease

Use With Caution

• Methotrexate: Controversial; safe in many patients but requires close monitoring
• Regular PFT monitoring and patient education about symptoms

Step 4. Advanced & Supportive Care:

• Oxygen therapy for hypoxemia.
• Pulmonary rehab for exercise tolerance.
• Palliative care integration for advanced disease.
• Lung transplantation in eligible progressive cases.

Algorithm for the management of RA-ILD. (Image Courtesy: Rodríguez GC, Villaverde V. Interstitial lung disease in patients with rheumatoid arthritis: a narrative review. Explor Musculoskeletal Dis. 2023;1:128–42. Available fromOpen Exploration. Licenced under CC by 4.0)

Prognosis of Rheumatoid Lung Disease

Pulmonary involvement in rheumatoid arthritis is one of the strongest predictors of reduced survival. Prognosis varies widely depending on the type of lung disease, radiologic pattern, and patient factors.

Overall Impact:

• Rheumatoid lung disease reduces life expectancy by ~3–10 years compared with RA patients without lung involvement.^[10]
• Interstitial lung disease (ILD) is the leading cause of RA-related pulmonary mortality.

Key Prognostic Factors

Poor Prognosis Indicators:

• UIP pattern on HRCT (median survival 3-5 years, similar to IPF)
• Male sex and advanced age at ILD onset
• History of smoking
• High RF or anti-CCP antibody titers
• Rapid decline in PFTs (≥10% fall in FVC over 6-12 months)

Better Prognosis Indicators:

• NSIP or organizing pneumonia patterns
• Early disease detection through screening
• Good response to immunosuppressive therapy
• Younger age and female sex

Subtype-Specific Outlook:

• UIP Pattern: Typically progressive with poor response to immunosuppression. Median survival resembles idiopathic pulmonary fibrosis, with most patients experiencing a steady decline despite treatment.^[11]
• NSIP Pattern: Often stabilizes or improves with appropriate immunosuppressive therapy. Long-term outcomes are generally more favorable, though some patients may develop progressive fibrosis.
• Organizing Pneumonia: Usually steroid-responsive with good initial outcomes. However, relapses are common, and some patients require long-term low-dose immunosuppression.
• Nodules and Pleural Disease: Generally follow a benign course unless complicated by cavitation, infection, or recurrent symptomatic effusions. These manifestations rarely directly contribute to mortality.
• Bronchiectasis: Causes chronic morbidity through recurrent infections but is less directly fatal compared to ILD. Quality of life can be significantly impacted.

Life Expectancy:

• Median survival of RA-ILD: 5–8 years after diagnosis, heavily dependent on ILD subtype.^[12]
• Mortality risk is threefold higher compared to RA without lung disease.

Long-Term Prognosis:

• Disease is often progressive despite treatment, highlighting the importance of early recognition.
• Multidisciplinary monitoring improves survival by allowing timely therapy escalation.
• Lung transplantation may extend survival in carefully selected patients, though outcomes are generally worse compared to other indications due to underlying systemic disease and immunosuppression requirements.

Complications of Rheumatoid Lung Disease

Rheumatoid lung disease predisposes patients to numerous secondary complications that may arise from the disease process itself, immunosuppressive treatments, or associated comorbidities. Recognition and management of these complications often determine long-term outcomes.

Pulmonary Complications:15Shaw, M., Collins, B. F., Ho, L. A., & Raghu, G. (2015). Rheumatoid arthritis-associated lung disease. European Respiratory Review, 24(135), 1. https://doi.org/10.1183/09059180.00008014

• Pulmonary Hypertension
• Respiratory Failure
• Recurrent Infections
• Pneumothorax / Bronchopleural Fistula
• Mass-like Nodules / Malignancy

Treatment-Related Complications:

• Drug-induced pneumonitis/fibrosis (methotrexate, leflunomide, anti-TNF agents)
• Infections due to immunosuppression (e.g., Pneumocystis jirovecii pneumonia)
• Cytotoxic drug toxicity (bone marrow suppression, hemorrhage with cyclophosphamide)

Systemic Complications:

• Deconditioning & exercise limitation due to chronic dyspnea
• Psychological burden (anxiety, depression, reduced quality of life)
• Accelerated atherosclerosis (shared inflammatory pathways between RA and lung disease)

Respiratory manifestations in rheumatoid arthritis. Percentages show the respective prevalence. (Image Courtesy: Alunno, Alessia, Gerli, Roberto, Giacomelli, Roberto, Carubbi, Francesco, Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis, BioMed Research International, 2017, 7915340, 8 pages, 2017. Available fromWiley. Licenced under CC by 4.0)

Prevention & Lifestyle Modifications in Rheumatoid Lung Disease

While not all pulmonary complications of rheumatoid arthritis (RA) can be prevented, several modifiable risk factors and supportive measures can reduce disease incidence, slow progression, and improve quality of life.

Risk Factor Modification:

• Smoking Cessation
• Occupational Exposure Avoidance

Vaccination:

• Influenza and pneumococcal vaccines are recommended to lower infection risk in immunosuppressed patients.
• Consider COVID-19 vaccination and boosters where appropriate.

Exercise & Pulmonary Rehabilitation:

• Structured pulmonary rehabilitation programs improve exercise tolerance, dyspnea, and emotional well-being.
• Simple daily walking or low-impact aerobic activity maintains lung capacity and cardiovascular fitness.

Nutritional & Lifestyle Support:

• A balanced diet rich in antioxidants and anti-inflammatory foods may help modulate systemic inflammation.
• Weight control reduces the work of breathing and cardiovascular strain.
• Alcohol moderation to reduce interactions with hepatotoxic drugs (e.g., methotrexate, leflunomide).

Drug Monitoring & Safety:

• Baseline and regular pulmonary function tests (PFTs) should be performed when using methotrexate or leflunomide.
• Early reporting of new respiratory symptoms during therapy.
• Switching to safer disease-modifying therapies if lung toxicity emerges.

Patient Education:

• Teach patients to recognize early warning signs: new/worsening cough, dyspnea, fevers.
• Encourage adherence to follow-up imaging and PFT schedules.
• Stress the importance of multidisciplinary care (rheumatology, pulmonology, physiotherapy).

Conclusion

Rheumatoid lung disease represents a significant yet frequently underrecognized complication of RA that can equal or exceed joint disease in its impact on morbidity and mortality. The spectrum of pulmonary involvement ranges from interstitial lung disease and pleural effusions to nodules and pulmonary hypertension, each requiring tailored diagnostic and therapeutic approaches.

The recognition that rheumatoid arthritis extends far beyond joint involvement has important implications for patient counseling, screening protocols, and treatment decisions. As our understanding of rheumatoid lung disease continues to evolve, early recognition and appropriate management remain the cornerstones of improving outcomes in this challenging complication.

References

[1] Laria, A., Lurati, A. M., Zizzo, G., Zaccara, E., Mazzocchi, D., Re, K. A., Marrazza, M., Faggioli, P., & Mazzone, A. (2022). Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. Frontiers in Medicine, 9, 837133. https://doi.org/10.3389/fmed.2022.837133

[2] Laria, A., Lurati, A. M., Zizzo, G., Zaccara, E., Mazzocchi, D., Re, K. A., Marrazza, M., Faggioli, P., & Mazzone, A. (2022). Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. Frontiers in Medicine, 9, 837133. https://doi.org/10.3389/fmed.2022.837133

[3] Shaw, M., Collins, B. F., Ho, L. A., & Raghu, G. (2015). Rheumatoid arthritis-associated lung disease. European Respiratory Review, 24(135), 1. https://doi.org/10.1183/09059180.00008014

[4] Demoruelle, M. K., Solomon, J. J., Fischer, A., & Deane, K. D. (2014). The lung may play a role in the pathogenesis of rheumatoid arthritis. International Journal of Clinical Rheumatology, 9(3), 295. https://doi.org/10.2217/ijr.14.23

[5] Sgalla, G., F Walsh, S. L., Sverzellati, N., Fletcher, S., Cerri, S., Dimitrov, B., Nikolic, D., Barney, A., Pancaldi, F., Larcher, L., Luppi, F., Jones, M. G., Davies, D., & Richeldi, L. (2018). “Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC Pulmonary Medicine, 18, 103. https://doi.org/10.1186/s12890-018-0670-0

[6] Wickrematilake, G. (2020). Complicated Rheumatoid Nodules in Lung. Case Reports in Rheumatology, 2020, 6627244. https://doi.org/10.1155/2020/6627244

[7] Hassan, A.M., Osman, A.A. & Ali, I.A. Pulmonary functions test in asymptomatic rheumatoid lung disease patients: a hospital-based study. Discov Med 1, 9 (2024). https://doi.org/10.1007/s44337-024-00013-x

[8] Shaw, M., Collins, B. F., Ho, L. A., & Raghu, G. (2015). Rheumatoid arthritis-associated lung disease. European Respiratory Review, 24(135), 1. https://doi.org/10.1183/09059180.00008014

[9] Sankari A, Chapman K, Ullah S. Idiopathic Pulmonary Fibrosis. [Updated 2024 Apr 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448162/

[10] Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev 2021; 30: 210011. doi: 10.1183/16000617.0011-2021

[11] Huang, Y., Lin, W., Chen, Z., Wang, Y., Huang, Y., & Tu, S. (2019). Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: Angel or demon? Drug Design, Development and Therapy, 13, 2111. https://doi.org/10.2147/DDDT.S204730

[12] Narváez, J. (2023). Moving forward in Rheumatoid Arthritis-Associated Interstitial Lung Disease Screening. Journal of Clinical Medicine, 13(18), 5385. https://doi.org/10.3390/jcm13185385

[13] Yang, S., Wang, J., Sun, D., Wang, Y., Xue, C., & Ye, Q. (2023). Disease progression in patients with usual interstitial pneumonia and probable UIP patterns on computed tomography with various underlying etiologies: A retrospective cohort study. Frontiers in Medicine, 10, 1246767. https://doi.org/10.3389/fmed.2023.1246767

[14] Boudal, A.M., Alsaigh, R.G., Alrajhi, N.N. et al. Exploring rheumatoid arthritis associated interstitial lung disease a retrospective study from two Saudi tertiary care centers. BMC Rheumatol 8, 32 (2024). https://doi.org/10.1186/s41927-024-00403-9

[15] Shaw, M., Collins, B. F., Ho, L. A., & Raghu, G. (2015). Rheumatoid arthritis-associated lung disease. European Respiratory Review, 24(135), 1. https://doi.org/10.1183/09059180.00008014